Abstract
The authors develop a model of investor reactions to new product development (NPD) failures in high technology firms. They propose that a firm's financial and managerial capabilities, and its strategic focus on R&D, influence investors' perceptions of the firm's market value after NPD failure and that these effects are contingent on the development stage of the failed product. Using data on 148 NPD failures of publicly traded biopharmaceutical firms and an event study methodology the authors find support for their hypotheses. They show that the relationships between a firm's (a) financial capabilities, (b) managerial capabilities, and (c) strategic focus on R&D, respectively, and the decline of firm market value after NPD failure are more negative for products that fail in late development stages than for products that fail in early development stages. The authors' results highlight the importance of a conjoint consideration of product-level and organizational-level effects in explaining investor reactions to NPD outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 985-1015 |
| Number of pages | 31 |
| Journal | Journal of Management |
| Volume | 39 |
| Issue number | 4 |
| DOIs | |
| State | Published - May 2013 |
Keywords
- biotechnology
- capabilities
- event study
- product development
- project failure